Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRENEOSHIFT-RCC
NCT07397611Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of casdatifan in clear cell renal cell carcinoma (ccRCC), sponsored by Dana-Farber Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07397611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07397611.